Last updated: 11/07/2018 08:31:40
PGx250: An Exploratory Pharmacogenetic Analysis of Asthma Exacerbations in African-Americans treated with Advair
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: PGx250: An Exploratory Pharmacogenetic Analysis of Asthma Exacerbations in African-Americans treated with Advair
Trial description: PGx250: An Exploratory Pharmacogenetic Analysis of Asthma Exacerbations in African-Americans treated with Advair
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Arg16gly ß2- Adrenergic Receptor Polymorphisms Are Not Associated with Asthma Exacerbations in Subjects of African Descent Treated with Fluticasone propionate Plus Salmeterol or Fluticasone propionate Alone. Presented at the Annual Meeting of the American Thoracic Society; May 15-20, 2009; San Diego, CA
Abstract: Polymorphisms in Interleukin 4 (IL4), Interleukin 13(IL13) and IL 4 receptor (IL4R) are associated with Asthma Exacerbations in African Americans. Presented at the American Society of Human Genetics Annual Meeting, October 22, 2009
Medical condition
Asthma
Product
fluticasone propionate, fluticasone propionate/salmeterol, salmeterol
Collaborators
Not applicable
Study date(s)
December 2008 to February 2009
Type
Not applicable
Phase
Not applicable
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2009-27-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website